{"protocolSection": {"identificationModule": {"nctId": "NCT00712296", "orgStudyIdInfo": {"id": "GCO 04-0206"}, "secondaryIdInfos": [{"id": "P01AT002647-02", "type": "NIH", "link": "https://reporter.nih.gov/quickSearch/P01AT002647-02"}], "organization": {"fullName": "Icahn School of Medicine at Mount Sinai", "class": "OTHER"}, "briefTitle": "Effectiveness of Chinese Herbal Therapy for Asthma", "officialTitle": "Center for Chinese Herbal Therapy for Asthma. Project #2-Clinical Effect of a Chinese Herbal Therapy in Human Asthma-Phase II"}, "statusModule": {"statusVerifiedDate": "2020-08", "overallStatus": "TERMINATED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-08", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2009-09-29", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-09-29", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-07-07", "studyFirstSubmitQcDate": "2008-07-07", "studyFirstPostDateStruct": {"date": "2008-07-09", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2011-09-22", "resultsFirstSubmitQcDate": "2020-08-12", "resultsFirstPostDateStruct": {"date": "2020-08-25", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2020-08-31", "lastUpdatePostDateStruct": {"date": "2020-09-16", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Xiu-Min Li", "investigatorTitle": "Professor, Pediatrics, Allergy and Immunology", "investigatorAffiliation": "Icahn School of Medicine at Mount Sinai"}, "leadSponsor": {"name": "Icahn School of Medicine at Mount Sinai", "class": "OTHER"}, "collaborators": [{"name": "National Center for Complementary and Integrative Health (NCCIH)", "class": "NIH"}]}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The purpose of this study is to determine the efficacy of an anti-asthma herbal medicine intervention (ASHMI) in adult asthmatics", "detailedDescription": "Asthma is a major public health problem worldwide, particularly in westernized societies and has continued to increase in prevalence over the past two decades. Inhaled corticosteroids have become the first-line treatment for persistent asthma even though side effects have been reported. New asthma medications, including leukotriene inhibitors and anti-IgE, have shown limited benefits. Patients have increasingly turned to complementary and alternative medicine (CAM) for treatment of their asthma, despite the uncertainty of its benefits due a lack of well-controlled scientific studies.\n\nWe have developed a Chinese herbal formula composed of 3 herbs called ASHMI. It has been previously shown in murine studies that ASHMI (a formula containing Ling Zhi, Ku Shen and Gan Cao) has therapeutic effects on the major pathogenic mechanisms of asthma-airway hyperreactivity, pulmonary inflammation, and airway remodeling, as well as a down-regulating of TH2 response. A subsequent study in 91 asthmatic patients in Weifang, China found ASHMI to be a safe and effective alternative to prednisone for treating asthma and exhibited a beneficial effect on TH1 and TH2 balance. Additionally, a Phase I study conducted in the United States showed good tolerability to ASHMI. Based on these preliminary studies, we hypothesize that ASHMI will be a safe medication in patients with asthma."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Asthma", "alternative medicine", "complementary medicine", "herbal therapy"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1", "PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 66, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "ASHMI 4", "type": "EXPERIMENTAL", "description": "ASHMI 4 capsules twice a day", "interventionNames": ["Drug: ASHMI 4"]}, {"label": "ASHMI 12", "type": "EXPERIMENTAL", "description": "ASHMI 12 capsules twice a day", "interventionNames": ["Drug: ASHMI 12"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo 6 capsules twice a day", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "ASHMI 4", "description": "4 capsules orally twice a day", "armGroupLabels": ["ASHMI 4"]}, {"type": "DRUG", "name": "ASHMI 12", "description": "12 capsules orally twice a day", "armGroupLabels": ["ASHMI 12"]}, {"type": "DRUG", "name": "Placebo", "description": "Placebo 6 capsules twice a day", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Glucose, Urea and Creatinine Phase I", "description": "Summary of Laboratory data for Glucose(mg/dL), Urea(mg/dL) and Creatinine(mg/dL) in subjects enrolled in Phase 1", "timeFrame": "1 week after receiving active drug or placebo"}, {"measure": "Sodium, Potassium, Chloride and CO2 Phase I", "description": "Summary of Laboratory data for Sodium(meq/L), Potassium(meq/L), Chloride(meq/L) and CO2 (meq/L) in subjects enrolled in Phase 1", "timeFrame": "1 week after receiving active drug or placebo"}, {"measure": "Serum Glutamic Pyruvic Transaminase and Serum Glutamic Oxaloacetic Transaminase in Phase I", "description": "Summary of Laboratory data for Serum glutamic pyruvic transaminase and Serum glutamic oxaloacetic transaminase in subjects enrolled in Phase 1", "timeFrame": "1 week after receiving active drug and placebo"}, {"measure": "Laboratory Results for White Blood Cell, Hemoglobin and Platelet in Phase I", "description": "Summary of Laboratory data for White Blood Cell(cells\\*10\\^3/uL), Hemoglobin(cells\\*10\\^3/uL) and Platelet(cells\\*10\\^3/uL)in subjects enrolled in Phase 1", "timeFrame": "1 week after receiving active drug and placebo"}, {"measure": "Hemoglobin Laboratory Results in Phase I", "description": "Summary of hemoglobin as Outcome measures included laboratory data for subjects enrolled in Phase 1", "timeFrame": "1 week"}, {"measure": "Laboratory Results for Glucose, Urea, Creatinine, Bilirubin Total and Bilirubin Direct Phase II Study", "description": "Summary of Laboratory data for Glucose(mg/dL), Urea(mg/dL), Creatinine(mg/dL), Bilirubin Total(mg/dL) and Bilirubin Direct(mg/dL)in subjects in Phase II\n\nLimited to Measurements before discontinuation of ASHMI treatment", "timeFrame": "28 weeks"}, {"measure": "Laboratory Results for Sodium,Potassium, Chloride and Bicarbonate in Phase II Study", "description": "Summary of Laboratory data for Sodium(meq/L), Potassium(meq/L), Chloride(meq/L) and Bicarbonate(meq/L)in subjects in Phase II\n\nLimited to Measurements before discontinuation of ASHMI treatment", "timeFrame": "28 weeks"}, {"measure": "Laboratory Results for Alkaline Phosphatase,Serum Glutamic Pyruvic Transaminase and Serum Glutamic Oxaloacetic Transaminase in Phase II Study", "description": "Summary of Laboratory data for Alkaline phosphatase(IU/L),Serum glutamic pyruvic transaminase(IU/L)and Serum glutamic oxaloacetic transaminase(IU/L) in subjects in Phase II study\n\nLimited to Measurements before discontinuation of ASHMI treatment", "timeFrame": "28 weeks"}, {"measure": "Laboratory Results for White Blood Cell Count and Platelet in Subjects in Phase II Study", "description": "Summary of Laboratory data for White Blood Cell Count(cells\\*10\\^3/uL) and Platelet (cells\\*10\\^3/uL)in Phase II study\n\nLimited to Measurements before discontinuation of ASHMI treatment", "timeFrame": "28 weeks"}, {"measure": "Laboratory Results for Hemoglobin in Subjects in Phase II Study", "description": "Summary of Laboratory data for hemoglobin(g/dL)in subjects in Phase II study.\n\nLimited to Measurements before discontinuation of ASHMI treatment", "timeFrame": "28 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Male and female subjects ages 18 through 55 and otherwise in good health as determined by medical history and physical examination\n* History of asthma documented by a physician for at least 6 months\n* Females of childbearing potential must be sexually inactive or take effective birth control measures, as deemed appropriate by the investigator, for the duration of the study\n* The subject agrees to participate in the study\n* Subjects must have one of the following:\n* one asthma-related unscheduled visit to an Emergency Department or clinic in the past 12 months\n* One overnight hospitalization in the past 12 months\n* Disturbed sleep more than twice in the past month\n* Asthma symptoms \u22658 times in the past month\n* use of a \u03b22-agonist \u22658 times in the past month\n* two short courses (3-7 days) of oral corticosteroids in the last 12 months\n* FEV1 \\<80% predicted AND Use of inhaled corticosteroid (ICS) for at least 1 month prior to enrollment\n\nExclusion Criteria:\n\n* Acute illness (such as cold, flu, etc.) within two weeks before the screening visit\n* Any history of systemic disease that in the investigator's opinion would preclude the subject from participating in this study, including hepatitis virus infection\n* History of chronic obstructive lung disease, emphysema, or other chronic respiratory condition\n* Abnormal hepatic function (ALT/AST and bilirubin \\>1.25 x upper limit of normal)\n* Abnormal bone marrow function (WBC \\<4 x 103/mm3; platelets \\<100 x 103/mm3; Hgb \\<11 g/dl)\n* Abnormal renal function (BUN and creatinine \\>1.25 x upper limit of normal)\n* Clinically significant abnormal electrocardiogram\n* FEV1 \\<50% predicted\n* Participation in another experimental therapy study within 30 days of this study\n* History of alcohol or drug abuse\n* Pregnant or lactating female subjects. Females of childbearing potential will need a negative serum pregnancy test at screening to be considered for this study\n* Subjects receiving treatment with Omalizumab or immunotherapy for asthma", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "55 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Juan P Wisnivesky, MD, DrPH", "affiliation": "Icahn School of Medicine at Mount Sinai", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Icahn School of Medicine at Mount Sinai", "city": "New York", "state": "New York", "zip": "10029", "country": "United States", "geoPoint": {"lat": 40.71427, "lon": -74.00597}}]}, "referencesModule": {"references": [{"pmid": "16159618", "type": "BACKGROUND", "citation": "Wen MC, Wei CH, Hu ZQ, Srivastava K, Ko J, Xi ST, Mu DZ, Du JB, Li GH, Wallenstein S, Sampson H, Kattan M, Li XM. Efficacy and tolerability of anti-asthma herbal medicine intervention in adult patients with moderate-severe allergic asthma. J Allergy Clin Immunol. 2005 Sep;116(3):517-24. doi: 10.1016/j.jaci.2005.05.029."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Phase I: Time frame 1 week; Phase II: Time frame 28 weeks. Participants from Phase I were invited to participate in Phase II and were re-randomized to all three arms of Phase II.", "recruitmentDetails": "Recruitment Period: 10/5/2006-3/12/2010\n\nLocation: Mount Sinai School of Medicine, New York, NY\n\nPhase I Participants Screened 55 Consented 35 Excluded 13 Withdrawn 2\n\nPhase II Participants Screened 183 Consented 76 Excluded 19 Screen failed 11", "groups": [{"id": "FG000", "title": "Active, Phase I", "description": "Patients received 3 daily doses in which 2, 4 or 6 ASHMI capsules were administered twice a day for 7 days."}, {"id": "FG001", "title": "Placebo, Phase I", "description": "Patients received placebo. (phase I)"}, {"id": "FG002", "title": "Active Phase II (ASHMI 4 Caps)", "description": "Patients received active drug. 4 caps twice a day."}, {"id": "FG003", "title": "Active, Phase II (ASHMI 12 Caps )", "description": "Patients received active drug. 12 caps twice a day."}, {"id": "FG004", "title": "Placebo, Phase II", "description": "Patients received placebo. (phase II)"}], "periods": [{"title": "Phase I ( 1 Week)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "12"}, {"groupId": "FG001", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "12"}, {"groupId": "FG001", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}]}, {"title": "Phase II (28 Weeks)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "15"}, {"groupId": "FG003", "numSubjects": "16"}, {"groupId": "FG004", "numSubjects": "15"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "comment": "ASHMI/Placebo was discontinued on 9/29/10.20 participants were re-randomized into the Phase II.", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "3"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "13"}, {"groupId": "FG003", "numSubjects": "15"}, {"groupId": "FG004", "numSubjects": "12"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "ASHMI/Placebo was discontinued on 9/29/10. 20 participants were re-randomized into the Phase II.", "groups": [{"id": "BG000", "title": "Active, Phase I", "description": "Patients received 3 daily doses in which 2, 4, or 6 ASHMI capsules were administered twice a day for 7 days."}, {"id": "BG001", "title": "Placebo, Phase I", "description": "Patients received placebo."}, {"id": "BG002", "title": "Active, Phase II (ASHMI 4 Caps )", "description": "Patients received active drug, 4 caps twice a day"}, {"id": "BG003", "title": "Active, Phase II (ASHMI 12 Caps)", "description": "Patients received active drug, 12 caps twice a day"}, {"id": "BG004", "title": "Placebo, Phase II", "description": "Patients received placebo."}, {"id": "BG005", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "12"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "15"}, {"groupId": "BG003", "value": "16"}, {"groupId": "BG004", "value": "15"}, {"groupId": "BG005", "value": "66"}]}], "measures": [{"title": "Age, Continuous", "populationDescription": "ASHMI/Placebo was discontinued on 9/29/10.20 participants were re-randomized into the Phase II.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"title": "Phase 1", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "12"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "20"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "32", "spread": "7"}, {"groupId": "BG001", "value": "31", "spread": "9"}, {"groupId": "BG005", "value": "31.6", "spread": "8.06"}]}]}, {"title": "Phase 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "15"}, {"groupId": "BG003", "value": "16"}, {"groupId": "BG004", "value": "15"}, {"groupId": "BG005", "value": "46"}]}], "categories": [{"measurements": [{"groupId": "BG002", "value": "44", "spread": "10"}, {"groupId": "BG003", "value": "44", "spread": "8"}, {"groupId": "BG004", "value": "40", "spread": "10"}, {"groupId": "BG005", "value": "42.7", "spread": "9.04"}]}]}]}, {"title": "Sex: Female, Male", "description": "This includes the number of males and females for the randomized study population for Phase I and Phase II", "populationDescription": "ASHMI/Placebo was discontinued on 9/29/10.20 participants were re-randomized into the Phase II.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "Phase 1", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "12"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "20"}]}], "categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG005", "value": "14"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG005", "value": "6"}]}]}, {"title": "Phase 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "15"}, {"groupId": "BG003", "value": "16"}, {"groupId": "BG004", "value": "15"}, {"groupId": "BG005", "value": "46"}]}], "categories": [{"title": "Female", "measurements": [{"groupId": "BG002", "value": "11"}, {"groupId": "BG003", "value": "14"}, {"groupId": "BG004", "value": "10"}, {"groupId": "BG005", "value": "35"}]}, {"title": "Male", "measurements": [{"groupId": "BG002", "value": "4"}, {"groupId": "BG003", "value": "2"}, {"groupId": "BG004", "value": "5"}, {"groupId": "BG005", "value": "11"}]}]}]}, {"title": "Race/Ethnicity, Customized", "populationDescription": "ASHMI/Placebo was discontinued on 9/29/10. 20 participants were re-randomized into the Phase II.", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Phase 1, White", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "12"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "20"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG005", "value": "23"}]}]}, {"title": "Phase 1, Black", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "12"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "20"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG005", "value": "18"}]}]}, {"title": "Phase 1, Hispanic", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "12"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "20"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG005", "value": "19"}]}]}, {"title": "Phase 1, Asian", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "12"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "20"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG005", "value": "5"}]}]}, {"title": "Phase 1, Other", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "12"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "20"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG005", "value": "1"}]}]}, {"title": "Phase 2, White", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "15"}, {"groupId": "BG003", "value": "16"}, {"groupId": "BG004", "value": "15"}, {"groupId": "BG005", "value": "46"}]}], "categories": [{"measurements": [{"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "5"}, {"groupId": "BG004", "value": "4"}, {"groupId": "BG005", "value": "14"}]}]}, {"title": "Phase 2, Black", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "15"}, {"groupId": "BG003", "value": "16"}, {"groupId": "BG004", "value": "15"}, {"groupId": "BG005", "value": "46"}]}], "categories": [{"measurements": [{"groupId": "BG002", "value": "6"}, {"groupId": "BG003", "value": "7"}, {"groupId": "BG004", "value": "2"}, {"groupId": "BG005", "value": "15"}]}]}, {"title": "Phase 2, Hispanic", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "15"}, {"groupId": "BG003", "value": "16"}, {"groupId": "BG004", "value": "15"}, {"groupId": "BG005", "value": "46"}]}], "categories": [{"measurements": [{"groupId": "BG002", "value": "4"}, {"groupId": "BG003", "value": "4"}, {"groupId": "BG004", "value": "4"}, {"groupId": "BG005", "value": "12"}]}]}, {"title": "Phase 2, Asian", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "15"}, {"groupId": "BG003", "value": "16"}, {"groupId": "BG004", "value": "15"}, {"groupId": "BG005", "value": "46"}]}], "categories": [{"measurements": [{"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "4"}, {"groupId": "BG005", "value": "4"}]}]}, {"title": "Phase 2, Other", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "15"}, {"groupId": "BG003", "value": "16"}, {"groupId": "BG004", "value": "15"}, {"groupId": "BG005", "value": "46"}]}], "categories": [{"measurements": [{"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "1"}, {"groupId": "BG005", "value": "1"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Glucose, Urea and Creatinine Phase I", "description": "Summary of Laboratory data for Glucose(mg/dL), Urea(mg/dL) and Creatinine(mg/dL) in subjects enrolled in Phase 1", "populationDescription": "For the Phase I study we used descriptive statistics to report the frequency of adverse events (AEs) among patients treated with ASHMI or placebo. Analysis was per intention to treat.", "reportingStatus": "POSTED", "anticipatedPostingDate": "2011-07", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "1 week after receiving active drug or placebo", "groups": [{"id": "OG000", "title": "Active Phase I Baseline", "description": "Baseline results for patients on ASHMI."}, {"id": "OG001", "title": "Active Phase I Post Treatment", "description": "Post Treatment results after 1 week for patients on ASHMI."}, {"id": "OG002", "title": "Placebo Phase I Baseline", "description": "Baseline results for participants who received placebo."}, {"id": "OG003", "title": "Placebo Phase I Post Treatment", "description": "Post Treatment results for participants who received placebo."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "8"}, {"groupId": "OG003", "value": "8"}]}], "classes": [{"title": "Glucose", "categories": [{"measurements": [{"groupId": "OG000", "value": "81", "spread": "12"}, {"groupId": "OG001", "value": "79", "spread": "9"}, {"groupId": "OG002", "value": "75", "spread": "14"}, {"groupId": "OG003", "value": "71", "spread": "7"}]}]}, {"title": "Urea", "categories": [{"measurements": [{"groupId": "OG000", "value": "13", "spread": "3"}, {"groupId": "OG001", "value": "13", "spread": "3"}, {"groupId": "OG002", "value": "16", "spread": "4"}, {"groupId": "OG003", "value": "17", "spread": "5"}]}]}, {"title": "Creatinine", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.8", "spread": "0.2"}, {"groupId": "OG001", "value": "0.8", "spread": "0.2"}, {"groupId": "OG002", "value": "0.9", "spread": "0.1"}, {"groupId": "OG003", "value": "0.9", "spread": "0.2"}]}]}]}, {"type": "PRIMARY", "title": "Sodium, Potassium, Chloride and CO2 Phase I", "description": "Summary of Laboratory data for Sodium(meq/L), Potassium(meq/L), Chloride(meq/L) and CO2 (meq/L) in subjects enrolled in Phase 1", "populationDescription": "For the Phase I study we used descriptive statistics to report the frequency of adverse events (AEs) among patients treated with ASHMI or placebo. Analysis was per intention to treat.", "reportingStatus": "POSTED", "anticipatedPostingDate": "2011-07", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "meq/L", "timeFrame": "1 week after receiving active drug or placebo", "groups": [{"id": "OG000", "title": "Active Phase I Baseline", "description": "Baseline results for patients on ASHMI."}, {"id": "OG001", "title": "Active Phase I Post Treatment", "description": "Post Treatment results after 1 week for patients on ASHMI."}, {"id": "OG002", "title": "Placebo Phase I Baseline", "description": "Baseline results for participants who received placebo."}, {"id": "OG003", "title": "Placebo Phase I Post Treatment", "description": "Post Treatment results for participants who received placebo."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "8"}, {"groupId": "OG003", "value": "8"}]}], "classes": [{"title": "Sodium (meq/L)", "categories": [{"measurements": [{"groupId": "OG000", "value": "139", "spread": "2"}, {"groupId": "OG001", "value": "140", "spread": "2"}, {"groupId": "OG002", "value": "139", "spread": "3"}, {"groupId": "OG003", "value": "139", "spread": "1"}]}]}, {"title": "Potassium (meq/L)", "categories": [{"measurements": [{"groupId": "OG000", "value": "4", "spread": "0.3"}, {"groupId": "OG001", "value": "4", "spread": "0.4"}, {"groupId": "OG002", "value": "4", "spread": "0.4"}, {"groupId": "OG003", "value": "4", "spread": "0.2"}]}]}, {"title": "Chloride (meq/L)", "categories": [{"measurements": [{"groupId": "OG000", "value": "103", "spread": "2"}, {"groupId": "OG001", "value": "103", "spread": "1"}, {"groupId": "OG002", "value": "102", "spread": "1"}, {"groupId": "OG003", "value": "102", "spread": "2"}]}]}, {"title": "Carbon dioxide (meq/L)", "categories": [{"measurements": [{"groupId": "OG000", "value": "24", "spread": "3"}, {"groupId": "OG001", "value": "23", "spread": "2"}, {"groupId": "OG002", "value": "24", "spread": "2"}, {"groupId": "OG003", "value": "24", "spread": "2"}]}]}]}, {"type": "PRIMARY", "title": "Serum Glutamic Pyruvic Transaminase and Serum Glutamic Oxaloacetic Transaminase in Phase I", "description": "Summary of Laboratory data for Serum glutamic pyruvic transaminase and Serum glutamic oxaloacetic transaminase in subjects enrolled in Phase 1", "populationDescription": "For the Phase I study we used descriptive statistics to report the frequency of adverse events (AEs) among patients treated with ASHMI or placebo. Analysis was per intention to treat.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "IU/L", "timeFrame": "1 week after receiving active drug and placebo", "groups": [{"id": "OG000", "title": "Active Phase I Baseline", "description": "Baseline results for patients on ASHMI."}, {"id": "OG001", "title": "Active Phase I Post Treatment", "description": "Post Treatment results after 1 week for patients on ASHMI."}, {"id": "OG002", "title": "Placebo Phase I Baseline", "description": "Baseline results for participants who received placebo."}, {"id": "OG003", "title": "Placebo Phase I Post Treatment", "description": "Post Treatment results for participants who received placebo."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "8"}, {"groupId": "OG003", "value": "8"}]}], "classes": [{"title": "Serum glutamic pyruvic transaminase (SGPT)", "categories": [{"measurements": [{"groupId": "OG000", "value": "19", "spread": "8"}, {"groupId": "OG001", "value": "20", "spread": "8"}, {"groupId": "OG002", "value": "21", "spread": "9"}, {"groupId": "OG003", "value": "20", "spread": "9"}]}]}, {"title": "Serum glutamic oxaloacetic transaminase (SGOT)", "categories": [{"measurements": [{"groupId": "OG000", "value": "20", "spread": "4"}, {"groupId": "OG001", "value": "20", "spread": "7"}, {"groupId": "OG002", "value": "24", "spread": "8"}, {"groupId": "OG003", "value": "24", "spread": "10"}]}]}]}, {"type": "PRIMARY", "title": "Laboratory Results for White Blood Cell, Hemoglobin and Platelet in Phase I", "description": "Summary of Laboratory data for White Blood Cell(cells\\*10\\^3/uL), Hemoglobin(cells\\*10\\^3/uL) and Platelet(cells\\*10\\^3/uL)in subjects enrolled in Phase 1", "populationDescription": "For the Phase I study we used descriptive statistics to report the frequency of adverse events (AEs) among patients treated with ASHMI or placebo. Analysis was per intention to treat.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "cells*10^3/uL", "timeFrame": "1 week after receiving active drug and placebo", "groups": [{"id": "OG000", "title": "Active Phase I Baseline", "description": "Baseline results for patients on ASHMI."}, {"id": "OG001", "title": "Active Phase I Post Treatment", "description": "Post Treatment results after 1 week for patients on ASHMI."}, {"id": "OG002", "title": "Placebo Phase I Baseline", "description": "Baseline results for participants who received placebo."}, {"id": "OG003", "title": "Placebo Phase I Post Treatment", "description": "Post Treatment results for participants who received placebo."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "8"}, {"groupId": "OG003", "value": "8"}]}], "classes": [{"title": "White Blood Cell", "categories": [{"measurements": [{"groupId": "OG000", "value": "7", "spread": "2"}, {"groupId": "OG001", "value": "7", "spread": "1"}, {"groupId": "OG002", "value": "7", "spread": "2"}, {"groupId": "OG003", "value": "7", "spread": "1"}]}]}, {"title": "Platelet", "categories": [{"measurements": [{"groupId": "OG000", "value": "292", "spread": "81"}, {"groupId": "OG001", "value": "238", "spread": "123"}, {"groupId": "OG002", "value": "281", "spread": "60"}, {"groupId": "OG003", "value": "273", "spread": "64"}]}]}]}, {"type": "PRIMARY", "title": "Hemoglobin Laboratory Results in Phase I", "description": "Summary of hemoglobin as Outcome measures included laboratory data for subjects enrolled in Phase 1", "populationDescription": "For the Phase I study descriptive statistics were used to report the frequency of adverse events (AEs) among patients treated with ASHMI or placebo. Analysis was per intention to treat.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "g/dL", "timeFrame": "1 week", "groups": [{"id": "OG000", "title": "Active Phase I Baseline", "description": "Baseline results for patients on ASHMI."}, {"id": "OG001", "title": "Active Phase I Post Treatment", "description": "Post Treatment results after 1 week for patients on ASHMI."}, {"id": "OG002", "title": "Placebo Phase I Baseline", "description": "Baseline results for participants who received placebo."}, {"id": "OG003", "title": "Placebo Phase I Post Treatment", "description": "Post Treatment results for participants who received placebo."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "8"}, {"groupId": "OG003", "value": "8"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "13", "spread": "0.9"}, {"groupId": "OG001", "value": "13", "spread": "1"}, {"groupId": "OG002", "value": "14", "spread": "2"}, {"groupId": "OG003", "value": "14", "spread": "1"}]}]}]}, {"type": "PRIMARY", "title": "Laboratory Results for Glucose, Urea, Creatinine, Bilirubin Total and Bilirubin Direct Phase II Study", "description": "Summary of Laboratory data for Glucose(mg/dL), Urea(mg/dL), Creatinine(mg/dL), Bilirubin Total(mg/dL) and Bilirubin Direct(mg/dL)in subjects in Phase II\n\nLimited to Measurements before discontinuation of ASHMI treatment", "populationDescription": "The Phase II study was terminated in September 2009 before the planned enrollment of 50 subjects was completed. As of September 29, 2009, the trial was discontinued in accordance with recommendations of the Data Safety Monitoring Board (DSMB).", "reportingStatus": "POSTED", "anticipatedPostingDate": "2011-09", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "28 weeks", "groups": [{"id": "OG000", "title": "Placebo Phase II Baseline", "description": "Patients received placebo. at baseline."}, {"id": "OG001", "title": "Active Phase II (ASHMI 4 Caps) Baseline", "description": "Patients received active drug. 4 caps twice a day. at baseline."}, {"id": "OG002", "title": "Active Phase II (ASHMI 12 Caps) Baseline", "description": "Patients received active drug. 12 caps twice a day. at baseline."}, {"id": "OG003", "title": "Placebo Phase II Visit 5", "description": "Patients received placebo. at visit 5."}, {"id": "OG004", "title": "Active Phase II (ASHMI 4 Caps) Visit 5", "description": "Patients received active drug. 4 caps twice a day. at visit 5."}, {"id": "OG005", "title": "Active Phase II (ASHMI 12 Caps) Visit 5", "description": "Patients received active drug. 12 caps twice a day. at visit 5."}, {"id": "OG006", "title": "Placebo Phase II Visit 10", "description": "Patients received placebo. at visit 10."}, {"id": "OG007", "title": "Active Phase II (ASHMI 4 Caps) Visit 10", "description": "Patients received active drug. 4 caps twice a day. at visit 10."}, {"id": "OG008", "title": "Active Phase II (ASHMI 12 Caps) Visit 10", "description": "Patients received active drug. 12 caps twice a day. at visit 10."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "15"}, {"groupId": "OG002", "value": "16"}, {"groupId": "OG003", "value": "10"}, {"groupId": "OG004", "value": "11"}, {"groupId": "OG005", "value": "10"}, {"groupId": "OG006", "value": "3"}, {"groupId": "OG007", "value": "2"}, {"groupId": "OG008", "value": "1"}]}], "classes": [{"title": "Glucose", "categories": [{"measurements": [{"groupId": "OG000", "value": "85", "spread": "28.4"}, {"groupId": "OG001", "value": "79.1", "spread": "12.1"}, {"groupId": "OG002", "value": "77.1", "spread": "12.8"}, {"groupId": "OG003", "value": "99.9", "spread": "45.9"}, {"groupId": "OG004", "value": "77.6", "spread": "8.8"}, {"groupId": "OG005", "value": "72.5", "spread": "12.6"}, {"groupId": "OG006", "value": "92.0", "spread": "12.0"}, {"groupId": "OG007", "value": "95.0", "spread": "38.2"}, {"groupId": "OG008", "value": "101.0"}]}]}, {"title": "Urea", "categories": [{"measurements": [{"groupId": "OG000", "value": "14.8", "spread": "4.1"}, {"groupId": "OG001", "value": "13.3", "spread": "5.4"}, {"groupId": "OG002", "value": "14.1", "spread": "5.4"}, {"groupId": "OG003", "value": "13.9", "spread": "2.6"}, {"groupId": "OG004", "value": "13.3", "spread": "2.5"}, {"groupId": "OG005", "value": "14.2", "spread": "4.2"}, {"groupId": "OG006", "value": "15.0", "spread": "2.6"}, {"groupId": "OG007", "value": "15.0", "spread": "8.5"}, {"groupId": "OG008", "value": "18.0"}]}]}, {"title": "Creatinine", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.9", "spread": "0.2"}, {"groupId": "OG001", "value": "0.8", "spread": "0.2"}, {"groupId": "OG002", "value": "0.8", "spread": "0.1"}, {"groupId": "OG003", "value": "0.8", "spread": "0.1"}, {"groupId": "OG004", "value": "0.9", "spread": "0.3"}, {"groupId": "OG005", "value": "0.9", "spread": "0.2"}, {"groupId": "OG006", "value": "1.0", "spread": "0.1"}, {"groupId": "OG007", "value": "0.9", "spread": "0.1"}, {"groupId": "OG008", "value": "0.3"}]}]}, {"title": "Bilirubin Total", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.4", "spread": "0.2"}, {"groupId": "OG001", "value": "0.4", "spread": "0.2"}, {"groupId": "OG002", "value": "0.4", "spread": "0.2"}, {"groupId": "OG003", "value": "0.5", "spread": "0.2"}, {"groupId": "OG004", "value": "0.4", "spread": "0.2"}, {"groupId": "OG005", "value": "0.3", "spread": "0.1"}, {"groupId": "OG006", "value": "0.4", "spread": "0.2"}, {"groupId": "OG007", "value": "0.4", "spread": "0.2"}, {"groupId": "OG008", "value": "0.2"}]}]}, {"title": "Bilirubin Direct", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.1", "spread": "0.0"}, {"groupId": "OG001", "value": "0.1", "spread": "0.0"}, {"groupId": "OG002", "value": "0.1", "spread": "0.0"}, {"groupId": "OG003", "value": "0.1", "spread": "0.0"}, {"groupId": "OG004", "value": "0.1", "spread": "0.0"}, {"groupId": "OG005", "value": "0.1", "spread": "0.0"}, {"groupId": "OG006", "value": "0.1", "spread": "0.1"}, {"groupId": "OG007", "value": "0.1", "spread": "0.0"}, {"groupId": "OG008", "value": "0.1"}]}]}]}, {"type": "PRIMARY", "title": "Laboratory Results for Sodium,Potassium, Chloride and Bicarbonate in Phase II Study", "description": "Summary of Laboratory data for Sodium(meq/L), Potassium(meq/L), Chloride(meq/L) and Bicarbonate(meq/L)in subjects in Phase II\n\nLimited to Measurements before discontinuation of ASHMI treatment", "populationDescription": "The Phase II study was terminated in September 2009 before the planned enrollment of 50 subjects was completed.", "reportingStatus": "POSTED", "anticipatedPostingDate": "2011-06", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "meq/L", "timeFrame": "28 weeks", "groups": [{"id": "OG000", "title": "Placebo Phase II Baseline", "description": "Patients received placebo at baseline"}, {"id": "OG001", "title": "Active Phase II (ASHMI 4 Caps ) Baseline", "description": "Patients received active drug. 4 caps twice a day at baseline"}, {"id": "OG002", "title": "Active Phase II (ASHMI 12 Caps) Baseline", "description": "Patients received active drug. 12 caps twice a day. Baseline"}, {"id": "OG003", "title": "Placebo Phase II Visit 5", "description": "Patients received placebo. at visit 5."}, {"id": "OG004", "title": "Active Phase II (ASHMI 4 Caps) Visit 5", "description": "Patients received active drug. 4 caps twice a day. at visit 5."}, {"id": "OG005", "title": "Active Phase II (ASHMI 12 Caps) Visit 5", "description": "Patients received active drug. 12 caps twice a day. at visit 5."}, {"id": "OG006", "title": "Placebo Phase II Visit 10", "description": "Patients received placebo. at visit 10."}, {"id": "OG007", "title": "Active Phase II (ASHMI 4 Caps) Visit 10", "description": "Patients received active drug. 4 caps twice a day. at visit 10."}, {"id": "OG008", "title": "Active Phase II (ASHMI 12 Caps) Visit 10", "description": "Patients received active drug. 12 caps a day. at visit 10."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "15"}, {"groupId": "OG002", "value": "16"}, {"groupId": "OG003", "value": "10"}, {"groupId": "OG004", "value": "11"}, {"groupId": "OG005", "value": "10"}, {"groupId": "OG006", "value": "3"}, {"groupId": "OG007", "value": "2"}, {"groupId": "OG008", "value": "1"}]}], "classes": [{"title": "Sodium", "categories": [{"measurements": [{"groupId": "OG000", "value": "140.6", "spread": "1.6"}, {"groupId": "OG001", "value": "140.3", "spread": "1.9"}, {"groupId": "OG002", "value": "140.5", "spread": "2.3"}, {"groupId": "OG003", "value": "139.5", "spread": "2.1"}, {"groupId": "OG004", "value": "140.1", "spread": "2.2"}, {"groupId": "OG005", "value": "139.6", "spread": "2.5"}, {"groupId": "OG006", "value": "139.7", "spread": "1.5"}, {"groupId": "OG007", "value": "140", "spread": "1.4"}, {"groupId": "OG008", "value": "140.0"}]}]}, {"title": "Potassium", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.9", "spread": "0.4"}, {"groupId": "OG001", "value": "4.1", "spread": "0.2"}, {"groupId": "OG002", "value": "4.1", "spread": "0.3"}, {"groupId": "OG003", "value": "4.1", "spread": "0.3"}, {"groupId": "OG004", "value": "4.1", "spread": "0.1"}, {"groupId": "OG005", "value": "4.1", "spread": "0.3"}, {"groupId": "OG006", "value": "4.2", "spread": "0.6"}, {"groupId": "OG007", "value": "4.1", "spread": "0.5"}, {"groupId": "OG008", "value": "3.8"}]}]}, {"title": "Chloride", "categories": [{"measurements": [{"groupId": "OG000", "value": "102.5", "spread": "2.2"}, {"groupId": "OG001", "value": "102.6", "spread": "1.9"}, {"groupId": "OG002", "value": "102.6", "spread": "2.5"}, {"groupId": "OG003", "value": "102.4", "spread": "2.2"}, {"groupId": "OG004", "value": "102.9", "spread": "3.2"}, {"groupId": "OG005", "value": "102.3", "spread": "3.5"}, {"groupId": "OG006", "value": "102.3", "spread": "0.6"}, {"groupId": "OG007", "value": "101.5", "spread": "2.1"}, {"groupId": "OG008", "value": "108.0"}]}]}, {"title": "Bicarbonate", "categories": [{"measurements": [{"groupId": "OG000", "value": "27.2", "spread": "2.7"}, {"groupId": "OG001", "value": "26.7", "spread": "2.5"}, {"groupId": "OG002", "value": "27.5", "spread": "1.6"}, {"groupId": "OG003", "value": "25.8", "spread": "2.4"}, {"groupId": "OG004", "value": "26.2", "spread": "2.0"}, {"groupId": "OG005", "value": "26.2", "spread": "1.7"}, {"groupId": "OG006", "value": "27.1", "spread": "1.6"}, {"groupId": "OG007", "value": "26.3", "spread": "2.9"}, {"groupId": "OG008", "value": "19.2"}]}]}]}, {"type": "PRIMARY", "title": "Laboratory Results for Alkaline Phosphatase,Serum Glutamic Pyruvic Transaminase and Serum Glutamic Oxaloacetic Transaminase in Phase II Study", "description": "Summary of Laboratory data for Alkaline phosphatase(IU/L),Serum glutamic pyruvic transaminase(IU/L)and Serum glutamic oxaloacetic transaminase(IU/L) in subjects in Phase II study\n\nLimited to Measurements before discontinuation of ASHMI treatment", "populationDescription": "The Phase II study was terminated in September 2009 before the planned enrollment of 50 subjects was completed. As of September 28, 2009, the trial was discontinued in accordance with recommendations of the Data Safety Monitoring Board (DSMB).", "reportingStatus": "POSTED", "anticipatedPostingDate": "2011-06", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "IU/L", "timeFrame": "28 weeks", "groups": [{"id": "OG000", "title": "Placebo Phase II Baseline", "description": "Patients received placebo. at baseline."}, {"id": "OG001", "title": "Active Phase II (ASHMI 4 Caps) Baseline", "description": "Patients received active drug. 4 caps twice a day. at baseline."}, {"id": "OG002", "title": "Active Phase II (ASHMI 12 Caps) Baseline", "description": "Patients received active drug. 12 caps twice a day. at baseline."}, {"id": "OG003", "title": "Placebo Phase II Visit 5", "description": "Patients received placebo. at visit 5."}, {"id": "OG004", "title": "Active Phase II (ASHMI 4 Caps) Visit 5", "description": "Patients received active drug. 4 caps twice a day. at visit 5."}, {"id": "OG005", "title": "Active Phase II (ASHMI 12 Caps) Visit 5", "description": "Patients received active drug. 12 caps twice a day. at visit 5."}, {"id": "OG006", "title": "Placebo Phase II Visit 10", "description": "Patients received placebo. at visit 10."}, {"id": "OG007", "title": "Active Phase II (ASHMI 4 Caps) Visit 10", "description": "Patients received active drug. 4 caps twice a day. at visit 10."}, {"id": "OG008", "title": "Active Phase II (ASHMI 12 Caps) Visit 10", "description": "Patients received active drug. 12 caps twice a day. at visit 10."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "15"}, {"groupId": "OG002", "value": "16"}, {"groupId": "OG003", "value": "10"}, {"groupId": "OG004", "value": "11"}, {"groupId": "OG005", "value": "10"}, {"groupId": "OG006", "value": "3"}, {"groupId": "OG007", "value": "2"}, {"groupId": "OG008", "value": "1"}]}], "classes": [{"title": "Alkaline phosphatase", "categories": [{"measurements": [{"groupId": "OG000", "value": "76.0", "spread": "22.2"}, {"groupId": "OG001", "value": "91.3", "spread": "23.0"}, {"groupId": "OG002", "value": "76.6", "spread": "24.7"}, {"groupId": "OG003", "value": "81.1", "spread": "24.8"}, {"groupId": "OG004", "value": "29.7", "spread": "25.7"}, {"groupId": "OG005", "value": "83.2", "spread": "25.0"}, {"groupId": "OG006", "value": "61.7", "spread": "18.5"}, {"groupId": "OG007", "value": "98.0", "spread": "5.7"}, {"groupId": "OG008", "value": "78.0"}]}]}, {"title": "Serum glutamic pyruvic transaminase (SGPT)", "categories": [{"measurements": [{"groupId": "OG000", "value": "23.9", "spread": "11.6"}, {"groupId": "OG001", "value": "21.9", "spread": "18.2"}, {"groupId": "OG002", "value": "21.3", "spread": "9.4"}, {"groupId": "OG003", "value": "26.9", "spread": "11.9"}, {"groupId": "OG004", "value": "22.0", "spread": "11.0"}, {"groupId": "OG005", "value": "22.5", "spread": "8.6"}, {"groupId": "OG006", "value": "24.3", "spread": "7.4"}, {"groupId": "OG007", "value": "14.5", "spread": "4.9"}, {"groupId": "OG008", "value": "32.0"}]}]}, {"title": "Serum glutamic oxaloacetic transaminase (SGOT)", "categories": [{"measurements": [{"groupId": "OG000", "value": "24.5", "spread": "8.4"}, {"groupId": "OG001", "value": "22.0", "spread": "9.3"}, {"groupId": "OG002", "value": "24.7", "spread": "7.3"}, {"groupId": "OG003", "value": "24.8", "spread": "8.1"}, {"groupId": "OG004", "value": "25.8", "spread": "9.6"}, {"groupId": "OG005", "value": "25.6", "spread": "8.7"}, {"groupId": "OG006", "value": "25.3", "spread": "8.9"}, {"groupId": "OG007", "value": "21.0", "spread": "7.1"}, {"groupId": "OG008", "value": "30.0"}]}]}]}, {"type": "PRIMARY", "title": "Laboratory Results for White Blood Cell Count and Platelet in Subjects in Phase II Study", "description": "Summary of Laboratory data for White Blood Cell Count(cells\\*10\\^3/uL) and Platelet (cells\\*10\\^3/uL)in Phase II study\n\nLimited to Measurements before discontinuation of ASHMI treatment", "populationDescription": "The Phase II study was terminated in September 2009 before the planned enrollment of 50 subjects was completed. As of September 28, 2009,the trial was discontinued in accordance with recommendations of the Data Safety Monitoring Board (DSMB).", "reportingStatus": "POSTED", "anticipatedPostingDate": "2011-06", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "cells*10^3/uL", "timeFrame": "28 weeks", "groups": [{"id": "OG000", "title": "Placebo Phase II Baseline", "description": "Patients received placebo. at baseline."}, {"id": "OG001", "title": "Active Phase II (ASHMI 4 Caps) Baseline", "description": "Patients received active drug. 4 caps twice a day. at baseline."}, {"id": "OG002", "title": "Active Phase II (ASHMI 12 Caps) Baseline", "description": "Patients received active drug. 12 caps twice a day. at baseline."}, {"id": "OG003", "title": "Placebo Phase II Visit 5", "description": "Patients received placebo. at visit 5."}, {"id": "OG004", "title": "Active Phase II (ASHMI 4 Caps) Visit 5", "description": "Patients received active drug. 4 caps twice a day. at visit 5."}, {"id": "OG005", "title": "Active Phase II (ASHMI 12 Caps) Visit 5", "description": "Patients received active drug. 12 caps twice a day. at visit 5."}, {"id": "OG006", "title": "Placebo Phase II Visit 10", "description": "Patients received placebo. at visit 10."}, {"id": "OG007", "title": "Active Phase II (ASHMI 4 Caps) Visit 10", "description": "Patients received active drug. 4 caps twice a day. at visit 10."}, {"id": "OG008", "title": "Active Phase II (ASHMI 12 Caps) Visit 10", "description": "Patients received active drug. 12 caps twice a day. at visit 10."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "15"}, {"groupId": "OG002", "value": "16"}, {"groupId": "OG003", "value": "10"}, {"groupId": "OG004", "value": "11"}, {"groupId": "OG005", "value": "10"}, {"groupId": "OG006", "value": "3"}, {"groupId": "OG007", "value": "2"}, {"groupId": "OG008", "value": "1"}]}], "classes": [{"title": "White Blood Cell Count", "categories": [{"measurements": [{"groupId": "OG000", "value": "7.2", "spread": "2.3"}, {"groupId": "OG001", "value": "7.6", "spread": "2.6"}, {"groupId": "OG002", "value": "7.2", "spread": "1.4"}, {"groupId": "OG003", "value": "6.5", "spread": "2.1"}, {"groupId": "OG004", "value": "7.5", "spread": "2.7"}, {"groupId": "OG005", "value": "6.8", "spread": "1.9"}, {"groupId": "OG006", "value": "7.9", "spread": "2.7"}, {"groupId": "OG007", "value": "9.4", "spread": "0.7"}, {"groupId": "OG008", "value": "6.2"}]}]}, {"title": "Platelet", "categories": [{"measurements": [{"groupId": "OG000", "value": "254.5", "spread": "74.6"}, {"groupId": "OG001", "value": "268.2", "spread": "49.0"}, {"groupId": "OG002", "value": "267.1", "spread": "89.5"}, {"groupId": "OG003", "value": "275.0", "spread": "86.3"}, {"groupId": "OG004", "value": "283.3", "spread": "58.5"}, {"groupId": "OG005", "value": "275.6", "spread": "119.6"}, {"groupId": "OG006", "value": "280.0", "spread": "133.8"}, {"groupId": "OG007", "value": "348.5", "spread": "29.0"}, {"groupId": "OG008", "value": "269.0"}]}]}]}, {"type": "PRIMARY", "title": "Laboratory Results for Hemoglobin in Subjects in Phase II Study", "description": "Summary of Laboratory data for hemoglobin(g/dL)in subjects in Phase II study.\n\nLimited to Measurements before discontinuation of ASHMI treatment", "populationDescription": "The Phase II study was terminated in September 2009 before the planned enrollment of 50 subjects was completed. As of September 28, 2009, the trial was discontinued in accordance with recommendations of the Data Safety Monitoring Board (DSMB).", "reportingStatus": "POSTED", "anticipatedPostingDate": "2011-06", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "g/dL", "timeFrame": "28 weeks", "groups": [{"id": "OG000", "title": "Placebo Phase II Baseline", "description": "Patients received placebo. at baseline."}, {"id": "OG001", "title": "Active Phase II (ASHMI 4 Caps) Baseline", "description": "Patients received active drug. 4 caps twice a day. at baseline."}, {"id": "OG002", "title": "Active Phase II (ASHMI 12 Caps) Baseline", "description": "Patients received active drug.12 caps twice a day. at baseline."}, {"id": "OG003", "title": "Placebo Phase II Visit 5", "description": "Patients received placebo. at visit 5."}, {"id": "OG004", "title": "Active Phase II (ASHMI 4 Caps) Visit 5", "description": "Patients received active drug. 4 caps twice a day. at visit 5."}, {"id": "OG005", "title": "Active Phase II (ASHMI 12 Caps) Visit 5", "description": "Patients received active drug. 12 caps twice a day. at visit 5."}, {"id": "OG006", "title": "Placebo Phase II Visit 10", "description": "Patients received placebo. at day 10."}, {"id": "OG007", "title": "Active Phase II (ASHMI 4 Caps) Visit 10", "description": "Patients received active drug. 4 caps twice a day. at visit 10."}, {"id": "OG008", "title": "Active Phase II (ASHMI 12 Caps) Visit 10", "description": "Patients received active drug.12 caps twice a day. at visit 10."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "15"}, {"groupId": "OG002", "value": "16"}, {"groupId": "OG003", "value": "10"}, {"groupId": "OG004", "value": "11"}, {"groupId": "OG005", "value": "10"}, {"groupId": "OG006", "value": "3"}, {"groupId": "OG007", "value": "2"}, {"groupId": "OG008", "value": "1"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "13.5", "spread": "1.4"}, {"groupId": "OG001", "value": "13.5", "spread": "1.6"}, {"groupId": "OG002", "value": "12.8", "spread": "1.2"}, {"groupId": "OG003", "value": "13.9", "spread": "1.2"}, {"groupId": "OG004", "value": "13.7", "spread": "1.4"}, {"groupId": "OG005", "value": "12.9", "spread": "1.5"}, {"groupId": "OG006", "value": "13.7", "spread": "1.7"}, {"groupId": "OG007", "value": "13.9", "spread": "1.5"}, {"groupId": "OG008", "value": "14.3"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "Phase I: 1 week Phase II: 28 weeks", "eventGroups": [{"id": "EG000", "title": "Active Phase I (ASHMI 2 Caps Twice a Day)", "description": "Patients received 2, 4, or 6 ASHMI capsules were administered twice daily for 7 days.", "seriousNumAffected": 0, "seriousNumAtRisk": 4, "otherNumAffected": 2, "otherNumAtRisk": 4}, {"id": "EG001", "title": "Placebo Phase I (2 Caps Twice a Day)", "description": "Patients received placebo. 2 caps twice a day.", "seriousNumAffected": 0, "seriousNumAtRisk": 2, "otherNumAffected": 2, "otherNumAtRisk": 2}, {"id": "EG002", "title": "Active Phase I (ASHMI 4 Caps)", "description": "Patients received active drug. 4 caps twice a day.", "seriousNumAffected": 0, "seriousNumAtRisk": 4, "otherNumAffected": 1, "otherNumAtRisk": 4}, {"id": "EG003", "title": "Placebo Phase I (4 Caps Twice a Day)", "description": "Patients received placebo. 4 caps twice a day.", "seriousNumAffected": 0, "seriousNumAtRisk": 4, "otherNumAffected": 2, "otherNumAtRisk": 4}, {"id": "EG004", "title": "Active Phase I (ASHMI 6 Caps)", "description": "Patients received active drug. 6 caps twice a day.", "seriousNumAffected": 0, "seriousNumAtRisk": 4, "otherNumAffected": 1, "otherNumAtRisk": 4}, {"id": "EG005", "title": "Placebo Phase I", "description": "Patients received placebo.", "seriousNumAffected": 0, "seriousNumAtRisk": 2, "otherNumAffected": 1, "otherNumAtRisk": 2}, {"id": "EG006", "title": "Active Phase II (ASHMI 4 Caps Twice a Day)", "description": "Patients received active drug.Based on revised adverse event criteria on January 2010.", "seriousNumAffected": 0, "seriousNumAtRisk": 15, "otherNumAffected": 2, "otherNumAtRisk": 15}, {"id": "EG007", "title": "Active Phase II (ASHMI 12 Caps)", "description": "Patients received active drug. 12 caps twice a day.", "seriousNumAffected": 0, "seriousNumAtRisk": 16, "otherNumAffected": 2, "otherNumAtRisk": 16}, {"id": "EG008", "title": "Placebo Phase II", "description": "Patients received placebo.", "seriousNumAffected": 0, "seriousNumAtRisk": 15, "otherNumAffected": 3, "otherNumAtRisk": 15}], "otherEvents": [{"term": "Upper respiratory tract infection", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 4}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 4}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG008", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}]}, {"term": "Increased Thirst", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 4}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}]}, {"term": "Body aches and fatigue associated with subject's typical prementrual syndrome", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 4}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}]}, {"term": "Transient upper extremity itchiness", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 4}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG008", "numEvents": 3, "numAffected": 3, "numAtRisk": 15}]}, {"term": "Insomnia", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numEvents": 1, "numAffected": 1, "numAtRisk": 2}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}]}, {"term": "Decreased total serum bicarbonate level", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 4}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 4}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}]}, {"term": "Back muscle injury", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 4}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}]}, {"term": "Sinusitis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}]}, {"term": "Glucosuria", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG008", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}]}, {"term": "Decreased Glucose Level", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG007", "numEvents": 2, "numAffected": 2, "numAtRisk": 16}, {"groupId": "EG008", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}]}, {"term": "Decreased Hemoglobin Level", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}]}, {"term": "Decreased White Blood Cell Count", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}]}, {"term": "Emergency room visit for asthma exacerbation", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG006", "numEvents": 2, "numAffected": 2, "numAtRisk": 15}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}]}, {"term": "Unscheduled physician visit for asthma exacerbation", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG008", "numEvents": 2, "numAffected": 2, "numAtRisk": 15}]}, {"term": "Electrocardiogram changes", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 4}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG008", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}]}, {"term": "Trichomonas in urine", "organSystem": "Renal and urinary disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 4}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}]}, {"term": "Proteinuria", "organSystem": "Renal and urinary disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG008", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}]}, {"term": "Increased Alkaline Phosphatase", "organSystem": "Renal and urinary disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG008", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}]}, {"term": "Increased Creatine", "organSystem": "Renal and urinary disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}]}, {"term": "Gastrointestinal symptoms", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 4}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 4}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 4}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG008", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 4}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}]}, {"term": "Elevated Liver Enzymes", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG008", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "The Phase II study was stopped after 46 subjects were randomized. Since the number of subjects and the follow-up information did not provide adequate power, all statistical analysis plan was changed to descriptive summaries for each group."}, "certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Xiu-Min Li, MD", "organization": "Icahn School of Medicine at Mount Sinai", "email": "Xiu-min.li@mssm.edu", "phone": "212-241-1755"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}}, "hasResults": true}